Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- ribonucleic acid
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 283821
For the Option Right of the Licensee to the Optional Territory Licensor grants a non-exclusive option right to obtain an exclusive license, with the right to grant sublicenses to Sublicensees, under Licensor Intellectual Property and Know-How; and a non-exclusive option right to obtain an exclusive sublicense, with the right to grant sub-sublicenses to Sub-sublicensees, under Sublicensed Intellectual Property, to research, develop, make, have made, import, use, sell and offer to sell the Licensed Product in the Field in the mutually agreed upon countries in the Optional Territory,
Licensed Compound means FE301, i.e., SGP130Fc fusion protein, an interleukin-6 inhibitor.
The patents are for FE301 composition; FE301 dosing; Fusion proteins comprising two soluble gp130 molecules; Optimized nucleotide sequences encoding sgp130; and Improved sgp130Fc dimers.
Optimized nucleotide sequences encoding sgp130 Patent No. 8,206,948
Olamkicept is a new recombinant protein inhibitor of the interleukin-6 pathway. Interleukin-6 is associated with numerous inflammatory conditions such as inflammatory bowel diseases (IBD) and rheumatoid arthritis.
IPSCIO Record ID: 237243
Licensor grants a non-exclusive license, without the right to sublicense, in the Territory to conduct preclinical research and/or pre-Phase II clinical trials ( or the equivalent of pre-Phase II clinical trials in the U.S. or other countries) involving the use of Licensed Products in indications outside of the Field of Use.
IPSCIO Record ID: 245716
Licensee desires to obtain an exclusive license to patents owned or controlled by Licensor, a sublicense to certain patents licensed from Bristol-Myers Squibb Company (â€œBMSâ€), along with any associated know-how, biologic materials, clinical data or other technology relating to IL-6 receptor monoclonal antibodies (identified as NI-1201), and their use in order to research, develop and commercialize products and services.
IPSCIO Record ID: 286023
The license s exclusive or non-exclusive on a patent by patent basis.
Licensed Product means any product that contains or comprises an Antibody, or any chemically modified Antibody, which recognizes TNF alpha. For the avoidance of doubt, Licensed Product shall not include non-Antibody inhibitors of TNF alpha.
The patents are titled Multichain Polypeptides or Proteins and Processes for their Production;
Recombinant Antibody; Humanized Antibodies; Protein Expression System; Process for obtaining Antibodies; Monovalent Antibody Fragments; and, Biological Products.
IBD Indication means the prevention, treatment or control of Crohnâ€™s Disease and/or ulcerative colitis in humans and/or animals.
RA Indication means the prevention, treatment or control of rheumatoid arthritis in humans.